×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| BLISS GVS PHARMA LTD. | 1739.57 | 210.53 | 1633.64 | 1.98 | 1,635 | 15.4 |
| SYNCOM FORMULATIONS (INDIA) LT | 1225.67 | 157.29 | 1165.47 | 0.21 | 1628 | 28.3 |
| JAGSONPAL PHARMACEUTICALS LTD. | 784.37 | 107.95 | 756.12 | 1.58 | 1590 | 37.3 |
Bliss GVS Pharma Limited, with Security Code 506197, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 143.4 | 109.0 | 171.3 | 161.3 | 163.8 | 149.0 | 182.6 | 179.6 | 156.0 | 163.4 |
| Expenses | 132.5 | 97.9 | 129.0 | 132.7 | 138.7 | 122.2 | 157.3 | 153.9 | 142.3 | 130.6 |
| Operating Profit | 10.9 | 11.1 | 42.3 | 28.7 | 25.1 | 26.7 | 25.4 | 25.7 | 13.7 | 32.8 |
| OPM % | 7.61% | 10.14% | 24.7% | 17.76% | 15.35% | 17.95% | 13.9% | 14.33% | 8.81% | 20.06% |
| Other Income | 6.5 | 6.5 | 10.6 | 7.9 | -32.6 | 6.8 | 8.4 | 11.7 | 9.4 | 10.6 |
| Interest | 5.0 | 1.3 | 1.2 | 1.8 | 1.5 | 1.2 | 3.4 | 0.7 | 1.3 | 5.1 |
| Depreciation | 4.0 | 5.4 | 5.7 | 6.2 | 6.2 | 6.3 | 6.4 | 7.0 | 7.4 | 7.7 |
| Profit before tax | 8.4 | 10.9 | 46.1 | 28.5 | 25.9 | 26.2 | 23.9 | 29.8 | 14.4 | 30.6 |
| Tax % | -27.7% | -31.3% | -26.4% | -27.4% | -24.8% | 25.7% | -28.7% | -29.3% | -20.2% | 31.1% |
| Net Profit | 6.1 | 7.5 | 33.9 | 20.7 | -11.5 | 19.4 | 17.0 | 21.1 | 11.5 | 21.1 |
| EPS in Rs | 0.59 | 0.71 | 3.19 | 1.95 | -1.08 | 1.81 | 1.62 | 2 | 0 | 1.98 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 205.7 | 184.8 | 159.5 | 211.9 | 200.7 | 198.1 | 183.6 | 217.7 | 210.4 | 198.0 |
| Expenses | 158.0 | 178.5 | 135.3 | 157.5 | 157.0 | 169.8 | 149.3 | 176.2 | 180.6 | 176.9 |
| Operating Profit | 47.7 | 6.2 | 24.2 | 54.4 | 43.7 | 28.3 | 34.3 | 41.5 | 29.8 | 21.1 |
| OPM % | 23.18% | 3.38% | 15.18% | 25.66% | 21.77% | 14.31% | 18.69% | 19.05% | 14.16% | 10.66% |
| Other Income | 5.6 | 3.0 | 5.1 | 12.6 | 5.4 | -23.6 | 4.1 | 5.0 | 15.3 | 12.1 |
| Interest | 1.3 | 5.1 | 1.5 | 1.4 | 2.1 | 1.9 | 1.5 | 3.8 | 1.1 | 1.7 |
| Depreciation | 4.6 | 4.9 | 6.2 | 6.4 | 7.0 | 6.8 | 6.8 | 7.0 | 7.6 | 8.0 |
| Profit before tax | 47.4 | -0.8 | 21.6 | 59.1 | 40.0 | 25.2 | 30.1 | 35.7 | 36.4 | 23.5 |
| Tax % | -37.2% | -562% | -33.6% | -27.2% | -27.4% | 24.4% | -26.5% | 28% | 29.1% | -28.6% |
| Net Profit | 29.8 | 3.5 | 14.4 | 43.0 | 29.1 | -4.9 | 22.1 | 25.7 | 25.8 | 16.7 |
| EPS in Rs | 2.64 | 0.33 | 1.38 | 3.98 | 2.6 | -0.86 | 1.93 | 2.29 | 2.27 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 9% |
| 3 Years: | 2% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -6% |
| 3 Years: | -9% |
| TTM: | -9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 6% |
| 3 Years: | 21% |
| 1 Year: | 18% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 3% |
| 3 Years: | 3% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -4% |
| 3 Years: | 44% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 6% |
| 3 Years: | 21% |
| 1 Year: | 18% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|